Catalent Revenue and Competitors

Claim your profile

Somerset, NJ USA



Total Funding



Estimated Revenue & Valuation

  • Catalent's estimated annual revenue is currently $4.2B per year.(i)
  • Catalent's estimated revenue per employee is $313,814
  • Catalent's total funding is $550M.
  • Catalent's current valuation is $18.5B. (January 2022)

Employee Data

  • Catalent has 13320 Employees.(i)
  • Catalent grew their employee count by 6% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
Add Company

Catalent Pharma Solutions, Inc. (Catalent) is a provider of advanced drug delivery and packaging technologies, and outsourced development, manufacturing, and packaging services to the global pharmaceutical and biotechnology industry. Its drug delivery and packaging technologies help its customers achieve their desired clinical and market outcomes and are used in many products. The Company’s business is organized in three segments: Oral Technologies, Sterile Technologies and Packaging Services. It has relationships with pharmaceutical and biotechnology customers. Catalent’s key customers include Pfizer, Johnson & Johnson, GlaxoSmithKline, Eli Lilly, Merck, Abbott, Genentech, Wyeth and Novartis. In March 2009, Bavaria Industriekapital AG announced that its affiliate has completed the purchase of Catalent Pharma Solutions\' Osny in France.



Total Funding


Number of Employees


Revenue (est)


Employee Growth %





Catalent News

2022-04-20 - Catalent snaps up NJ cell therapy plant for $44.5M days after ...

Days after throwing down $350 million to beef up biologics manufacturing in Indiana, high-flying CDMO Catalent is buying a cell therapy plant on the East...

2022-04-20 - Catalent Acquires Cell Therapy Mfg. Facility

Catalent Acquires Erytech's Commercial-Scale Cell Therapy Mfg. Facility. 30,900-sq.-ft. facility in Princeton, NJ houses 16 suites for cGMP...

2022-04-20 - Catalent acquires New Jersey cell therapy development and ...

Catalent has acquired a commercial-scale cell therapy manufacturing facility in Princeton, New Jersey, from Erytech Pharma for $44.5m.

2021-11-18 - Catalent Experts to Discuss Evolving Strategies for Global Clinical Supply at Upcoming Conferences

SOMERSET, N.J. (PRWEB) November 18, 2021 Catalent, a global leader in clinical supply services, today announced that three of its experts will be speaking on current market trends and strategies within the industry at two upcoming conferences, Outsourcing in Clinical Trials East Asia, and Outso ...